Lecanemab is a lab-made antibody that targets and removes toxic clumps of amyloid-beta protein from the brain, slowing the progression of early Alzheimer’s disease. Unlike some earlier Alzheimer’s antibodies that primarily latch onto mature amyloid plaques, lecanemab has a strong preference for smaller, soluble forms of amyloid called protofibrils, which many researchers now consider the most damaging form of the protein.
What Lecanemab Targets in the Brain
In Alzheimer’s disease, a protein fragment called amyloid-beta misfolds and begins sticking together. It starts as individual pieces (monomers), clusters into small soluble clumps (protofibrils), and eventually hardens into the dense plaques visible on brain scans. For years, treatments focused on those mature plaques. Lecanemab takes a different approach by going after the earlier, soluble stage.
Lecanemab binds to protofibrils with roughly 1,000 times greater affinity than it has for individual amyloid monomers, and about 10 times greater affinity for protofibrils than for the dense fibrils that make up mature plaques. This selectivity matters because protofibrils circulate freely between brain cells, where they can damage synapses and trigger inflammation. Mature plaques, while abnormal, are relatively inert by comparison. By flagging protofibrils, lecanemab recruits the brain’s immune cells to engulf and clear them before they accumulate further.
Comparative studies using brain tissue at different stages of Alzheimer’s pathology illustrate the distinction. At earlier stages of amyloid buildup, lecanemab bound much more strongly than competing antibodies like aducanumab or gantenerumab, consistent with its preference for smaller aggregates. At more advanced stages dominated by dense plaques, aducanumab bound more strongly, reflecting its affinity for larger deposits.
How Treatment Is Given
Lecanemab (sold as Leqembi) is dosed at 10 mg per kilogram of body weight, delivered as an intravenous infusion over about one hour, once every two weeks. That biweekly schedule continues for 18 months. After that initial period, patients can either continue at the same pace or transition to a maintenance schedule: IV infusions once every four weeks, or weekly self-administered injections at home using an autoinjector device.
Before starting treatment, you need a confirmed diagnosis of amyloid buildup in the brain. This is typically established through either an amyloid PET scan or a cerebrospinal fluid test showing biomarkers consistent with Alzheimer’s. A baseline brain MRI is also required, and additional MRIs are scheduled at several points during treatment to monitor for side effects.
Who Is Eligible
The FDA approved lecanemab for people with Alzheimer’s disease, specifically those in the mild cognitive impairment or mild dementia stage. It is not indicated for moderate or advanced Alzheimer’s, because the clinical trials only enrolled people in those earlier phases. The logic is straightforward: clearing amyloid is most likely to help when cognitive decline is still in its early stages and there’s more brain function left to preserve.
Genetic testing for a gene variant called ApoE ε4 is recommended before starting treatment. This gene variant, carried by a large portion of Alzheimer’s patients, significantly affects the risk of a key side effect. Doctors are expected to discuss what the test results mean for your individual risk profile before you begin infusions.
Brain Swelling and Bleeding Risk
The most important safety concern with lecanemab is a set of brain changes called ARIA, short for amyloid-related imaging abnormalities. These come in two forms: brain swelling (ARIA-E) and tiny brain bleeds or iron deposits (ARIA-H). Most cases show up on MRI scans without causing noticeable symptoms, which is why regular imaging is built into the treatment schedule.
In pooled clinical trial data, about 12.6% of patients on lecanemab developed brain swelling visible on MRI, and 16.9% showed signs of microbleeds. Only about 2.8% experienced symptoms from the swelling, which can include headache, confusion, dizziness, or visual changes. About 8.2% of patients had both types of ARIA at the same time.
Your ApoE ε4 status is the strongest predictor of whether you’ll develop ARIA. Compared to people who don’t carry the variant, those with one copy of ApoE ε4 have roughly 1.5 times the risk of ARIA, while those with two copies face about 3.5 times the risk. This gene-dose effect is why genetic testing before treatment has become standard practice. The overall pooled ARIA incidence across lecanemab trials was about 19%, with the rate climbing significantly for homozygous carriers.
What the Drug Actually Achieves
Lecanemab does not stop or reverse Alzheimer’s disease. What it does is slow the rate of cognitive and functional decline. In the pivotal Clarity AD trial, patients on lecanemab declined about 27% more slowly than those on placebo over 18 months, as measured on a scale tracking memory, judgment, and daily activities. That translates to a modest but real difference in how quickly someone loses the ability to manage finances, follow conversations, or handle routine tasks.
The drug also substantially reduces amyloid plaque levels in the brain. Most patients treated for 18 months shift from amyloid-positive to amyloid-negative on PET scans. Whether this plaque clearance continues to provide benefit beyond 18 months, and whether the maintenance dosing preserves those gains, are questions that longer-term follow-up data will eventually answer.
For patients and families weighing the decision, the calculus involves balancing a measurable but modest slowing of decline against the inconvenience of biweekly infusions, the cost of treatment, regular MRI monitoring, and a meaningful risk of brain swelling or microbleeds, particularly for those carrying ApoE ε4 variants.